Table 2 Treatment groups and doses

A) Regorafenib

A₁:40µM regorafenib

A₂: Nano-particles containing 40 µM regorafenib (RDMP)

A₃: Nano-particles containing 40 µM regorafenib (RDMP) and 156nM siRNA

B) Quercetin

C₁: 8.2 µM quercetin = IC₁₀

C₂: 28.7 µM quercetin = IC₂₀

C₃: 65.7 µM quercetin = IC₃₀

C) Regorafenib/ Quercetin

B₁: 40µM regorafenib and 8.2 µM quercetin

B₂: 40µM regorafenib and 28.7 µM quercetin

B₃: 40µM regorafenib and 65.7 µM quercetin

D) QDMP /siRNA

D₁: Nano-particles containing 8.2 µM quercetin (QDMP) and 11 nM siRNA

D₂: Nano-particles containing 28.7 µM quercetin (QDMP) and 35.8 nM siRNA

D₃: Nano-particles containing 65.7 µM quercetin (QDMP) and 88 nM siRNA

E) NP control

E₁: Nano-particles containing 156nM siRNA

E₂: 156 nM non-targeted-siRNA

F) Control

F₁; cancerous cells without treatment

F₂; resistant cancerous cells without treatment